In the US, 1 in 7 adults are experiencing some type of chronic kidney disease caused by diabetes. The new approval therefore allows doctor to prescribe Ozempic to lower the risk of kidney failure, ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.